- GlobeNewswire•5 days agoEpizyme Establishes Collaboration with Foundation Medicine to Support Tazemetostat Phase 2 Clinical Trial
CAMBRIDGE, Mass., Sept. 21, 2016-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement ...
- GlobeNewswire•11 days agoEpizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development with First-in-Class PRMT5 Inhibitor
CAMBRIDGE, Mass., Sept. 15, 2016-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from GlaxoSmithKline. ...
Epizyme, Inc. (EPZM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||9.63 - 9.63|
|52wk Range||7.02 - 18.29|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.90|
|Avg Vol (3m)||378,271|
|Dividend & Yield||N/A (N/A)|